Health Canada is strengthening the required side effect warnings on prescriptions of Reglan so that they include more information regarding the likelihood of someone developing debilitating Tardive dyskinesia.

Reglan is the brand name of the drug Metoclopramide which has been used for decades to as an anti-emetic & prokinetic drug. Health Canada is the department which sets health policy within Canada. Health Canada has come out with stronger warnings regarding the major side effect of Tardive dyskinesia. The new warnings will now be required for all prescriptions of Reglan. Continue reading “Reglan Tardive Dyskinesia Side Effect Warnings Boosted In Canada” »

In a 5-4 ruling today the Supreme Court ruled that generic drug manufactures can not be held liable for failing to properly warn about known adverse reactions to their generic versions of brand name drugs.

The ruling was prompted by a lawsuit from two women (Gladys Mensing and Julie Demahy) who developed tardive dyskinesia after taking a generic form of Reglan(metoclopramide). Tardive dyskinesia is a severe neurological disorder that causes degradation of motor skills & tremors. The symptoms are similar to those found in Parkinson’s Disease. Reglan is a motility drug that goes beyond the blood brain barrier & is used in the USA for treatment of things like Gastroparesis & acid reflux. While safer alternatives are available outside the USA, such as Domperidone, there aren’t really any viable alternatives in the USA besides the herbal Iberogast or Erythromycin(which has it’s own risks). Continue reading “Supreme Court’s Reglan Ruling Detrimental To Patient’s Rights” »

Treatments For Gastroparesis

September 8th, 2010 - Written by - 2 comments

I am posting this information up for people who are dealing with GP or knows someone who is. These are treatment options that go towards the heart of the problem to hopefully improve quality of life. There are additional drugs that people may add such as proton pump inhibitor(heartburn medication), anti-emetic(nausea suppression). Continue reading “Treatments For Gastroparesis” »

Metozolv, Same Drug Different Branding

September 11th, 2009 - Written by - Leave a Comment

I received an e-mail today regarding a “new” prokinetic gastroparesis drug called “Metozolv”. I was thinking of even writing to the company behind it(Salix) to thank them for researching new drugs to treat gastroparesis. However, my jubilation was cut short upon further research I find that this is merely a new brand name for the same drug that is on the market now, called “metoclopramide HCI“. I know metoclopramide by the name of Reglan during my battle with gastroparesis. Reglan carries a “black box” warning from the FDA, which is the strongest warning a drug can carry. This is in relation dangerous side effects known as Tardive Dyskinesia. Reglan has been subject to a lawsuit due to these side effects.

What really angers me is the drug domperidone(also known as Motilium) has been proven to be much safer, but has failed to be marketed or approved for distribution in the United States. You can get it from a compounding pharmacy only if your doctor is willing to write the proper prescription. Most doctors aren’t willing to write a specific prescription for this task as it’s too much hassle and they like to live inside their safe bubble, even if their safe bubble means giving patients unsafe drugs. I tried with my doctor and he was much more willing to prescribe me Zelnorm as an alternative to Reglan. Zelnorm has actually been recalled due to adverse side effects! It’s main purpose was for IBS-C(constipation) where the patient is female. Firstly I am a male. Secondly the drug had problems where it apparently would cut off circulation to the intestines for some people.

Hopefully there will be further research done to improve treatments for gastroparesis sufferers. It would be nice if there really was a company out there blazing a new trail rather than trying to make money off of a dangerous drug.

Copyright © 2017 The Digestion Blog - Mark & Gabriel Hedges.

Privacy Policy